Sonoma pharmaceuticals and microsafe group announce that nanocyn(r) disinfectant & sanitizer has been approved by the australian tga as effective against candida auris and c-diff

Boulder, co / accesswire / august 26, 2024 / sonoma pharmaceuticals, inc. (nasdaq:snoa), a global healthcare leader developing and producing patented microcyn® technology based stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, and its partner, the microsafe group dmcc, announce that the australian therapeutic goods administration (tga) has approved extended claims for nanocyn® disinfectant and sanitizer, which is manufactured by sonoma for its partner microsafe using sonoma's patented microcyn® technology. nanocyn® was previously approved by the tga and entered into the australian register of therapeutic goods with a 15 second kill time against sars-cov-2 (covid 19), and a 30 second kill time against norovirus (gastro), influenza a (h1n1), and bacteria, such as staphylococcus aureus (mrsa), e.
SNOA Ratings Summary
SNOA Quant Ranking